OM — Outset Medical, Inc.

Summary of OM Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $29.4 million, a 3% increase year-over-year.
• Product Revenue: $20.6 million, slightly up from $20.3 million in Q3 2024.
  • Console Sales: $8.3 million.
  • Consumable Sales: $12.2 million.
• Service Revenue: $8.9 million, a 6% increase from $8.4 million in the prior year.
• Recurring Revenue: $21.1 million, slightly ahead of Q3 2024.
• Gross Margin: Non-GAAP gross margin reached 39.9%, with product gross margin at 45.7%.
• Operating Loss: Non-GAAP operating loss was $10.4 million, down 35% from $16.1 million in Q3 2024.
• Cash Position: Ended the quarter with $182 million in cash and equivalents, using approximately $6 million in cash during the quarter.

2. Strategic Updates and Business Highlights

• Sales Process Transformation: Significant progress made in transforming the sales process and strengthening the sales team, with a focus on enterprise-wide insourcing.
• Customer Demand: Continued growth in hospital demand for insourcing dialysis, with an 8% increase in Tableau console sales and a 20% increase in average deal size.
• Clinical Evidence: Positive clinical outcomes presented at the Kidney Week Conference, reinforcing the advantages of insourcing with Tableau.
• Leadership Change: Resignation of the head of sales, with the sales team now reporting directly to the CEO during the search for a new leader.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Revised to $115 million to $120 million, down from $122 million to $126 million, reflecting timing shifts in deal closures.
• Gross Margin Expectations: Anticipated to remain in the high 30% range for the full year.
• Operating Expenses: Expected to be in the low $90 million range for 2025.
• Cash Utilization: Projected to use less than $50 million in cash for 2025, a significant reduction from over $100 million in 2024.

4. Bad News, Challenges, or Points of Concern

• Sales Execution Shortfall: Q3 results fell short of expectations due to delays in closing large deals, which are now expected to close in Q4 2025 and into 2026.
• Leadership Transition Risks: The departure of the head of sales may lead to internal disruption and affect sales execution in the near term.
• Forecasting Challenges: Issues with aligning customer ordering patterns with actual treatment utilization, particularly among large acute care customers, may impact revenue visibility.

5. Notable Q&A Insights

• Deal Timing and Guidance: Management acknowledged that the revised guidance reflects a conservative approach due to the leadership change and the timing of large deals. They confirmed that no deals have fallen out of the pipeline.
• Sales Leadership Search: The new sales leader will need a strong background in capital equipment and enterprise sales, with an emphasis on strategic execution and team development.
• Future Growth Outlook: While the company aims for higher growth rates, they recognize the need for improved execution on deal timing and customer engagement to achieve this.
• Home Channel Performance: Stable retention rates in the home dialysis segment, with continued growth in partnerships with major organizations, indicating a positive outlook for this segment.

Overall, while OM showed some positive metrics and strategic initiatives, challenges related to sales execution and leadership changes present risks that the company is actively addressing.